Gelsyn-3 Injection denials in California external review
In the California DMHC record, independent physician reviewers decided 14 published external-review cases involving Gelsyn-3 Injectionand overturned the plan’s denial in 100%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Conditions behind Gelsyn-3 Injection denials
| Category | Decisions | Overturned |
|---|---|---|
| Osteoarthritis Of The Knee | 10 | 100% |
| Knee Osteoarthritis | 3 | 100% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The patient requested authorization and coverage for bilateral GelSyn-3 (hyaluronic) series knee injections.Evidence from randomized trials and current medical literature have revealed varied results as viscosupplementation may relieve some knee pain in individuals with osteoarthritis. However, the evidence concerning for which individuals viscosupplementation may benefit is unknown. In an effort to establish a more effective treatment, different studies have tried mixing hyaluronic acid with corticosteroids, platelet-rich plasma, and other agents. However, guidelines indicate that confirmatory evidence is limited and not conclusive. As such, research does not currently recommend viscosupplementation as routine treatment for osteoarthritis of the knees.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for bilateral Gelsyn-3 injections. Evidence from systematic reviews and randomized controlled trials indicate that although viscosupplementation may relieve knee pain in some patients with osteoarthritis, data has not established which patients will benefit. Several studies have tried mixing hyaluronic acid with corticosteroids, platelet-rich plasma, and other agents, to increase its effectiveness. Professional study guidelines indicate that the data on the safety and efficacy of viscosupplementation remain inconclusive. As such, the study does not currently recommend viscosupplementation as routine treatment for osteoarthritis of the knees.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Gelsyn-3 Injection, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY